US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eupraxia Pharmaceuticals

3.48

+0.19005.78%

Volume:33.61K

Turnover:115.35K

Market Cap:124.76M

PE:-4.55

High:3.49

Open:3.38

Low:3.38

Close:3.29

Loading ...

Overview Company News Filings

TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks

Simply Wall St.

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation

Simply Wall St.

Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress

Eupraxia Pharmaceuticals Q4 Net Profit $(7.5)M Up From $(10.6)M YoY

Press Release: Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum

Eupraxia Pharmaceuticals Shares Rise on Positive Drug Trial Data

Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential

Top Premarket Decliners

MT Newswires Live

Eupraxia Pharmaceuticals Taps Alex Rothwell as CFO

Press Release: Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia Pharmaceuticals Unveils Promising Drug Delivery Data

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals Hosts Webinar on Digestive Disorders

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Reports Promising Trial Results

Eupraxia reports data from RESOLVE Phase 1b/2a trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EPRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EPRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPRX\",,,,,undefined,":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":3.48,"timestamp":1745265600000,"preClose":3.29,"halted":0,"volume":33605,"delay":0,"floatShares":24915816,"shares":35849353,"eps":-0.764151,"marketStatus":"Pre-Mkt","change":0.19,"latestTime":"04-22 04:22:09 EDT","open":3.38,"high":3.49,"low":3.38,"amount":115352.4994765,"amplitude":0.033435,"askPrice":5.55,"askSize":74,"bidPrice":1.4,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.764151,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":3.485,"postHourTrading":{"tag":"盘后","latestPrice":3.48,"preClose":3.48,"latestTime":"19:35 EDT","volume":16011,"amount":55076.9929,"timestamp":1745278513511},"volumeRatio":7.067892176283566},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPRX\",,,,,undefined,":{"symbol":"EPRX","floatShares":24915816,"roa":"-61.14%","roe":"-157.31%","lyrEps":-0.764151,"volumeRatio":7.067892176283566,"shares":35849353,"dividePrice":0,"high":3.49,"amplitude":0.033435,"preClose":3.29,"low":3.38,"week52Low":2.2,"pbRate":"73.40","week52High":4.48,"institutionHeld":0,"latestPrice":3.48,"committee":0.459854,"eps":-0.764151,"divideRate":0,"volume":33605,"delay":0,"ttmEps":-0.764151,"open":3.38,"prevYearClose":3.17,"prevWeekClose":3.29,"prevMonthClose":3.28,"prevQuarterClose":3.28,"fiveDayClose":3.025,"twentyDayClose":3.8226,"sixtyDayClose":3.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528064009","title":"TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2528064009","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528064009?lang=en_us&edition=fundamental","pubTime":"2025-04-18 21:05","pubTimestamp":1744981504,"startTime":"0","endTime":"0","summary":"The Canadian market has shown resilience, with the TSX rising over 2% recently, even as global markets grapple with tariff uncertainties and economic pressures. In such a climate, investors often look beyond the larger indices to find opportunities in lesser-known areas like penny stocks. Although the term \"penny stocks\" might seem outdated, these smaller or newer companies can offer significant potential for growth when backed by strong financials and sound fundamentals.Calfrac Well Services, with a market cap of CA$292.88 million, recently reported a net loss for Q4 2024 amid declining sales. The company has seen significant debt reduction over the past five years, yet its current net debt to equity ratio remains high at 42.4%. While short-term and long-term liabilities are covered by assets, interest payments are not well covered by earnings. Recent executive changes could impact future strategy and operations. Despite negative earnings growth last year, Calfrac is forecasted to gro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tsx-penny-stock-highlights-calfrac-130504171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2521074734","title":"Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521074734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521074734?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:55","pubTimestamp":1742817357,"startTime":"0","endTime":"0","summary":"In a report released today, Gary Nachman from Raymond James maintained a Buy rating on Eupraxia Pharmaceuticals (EPRX – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","EPRX"],"gpt_icon":0},{"id":"2521294217","title":"Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2521294217","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521294217?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:13","pubTimestamp":1742652834,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.Given this risk, we thought we'd take a look at whether Eupraxia Pharmaceuticals  shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-watching-eupraxia-141354176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EPRX","BK4090","TSE"],"gpt_icon":0},{"id":"2521418973","title":"Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2521418973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521418973?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:09","pubTimestamp":1742508545,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. Eupraxia Pharmaceuticals announced its fourth quarter 2024 financial results, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-strong-q4-2024-results-and-operational-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-strong-q4-2024-results-and-operational-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX","LU2065732104.USD","PRGS","BK4097"],"gpt_icon":0},{"id":"2521492022","title":"Eupraxia Pharmaceuticals Q4 Net Profit $(7.5)M Up From $(10.6)M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2521492022","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521492022?lang=en_us&edition=fundamental","pubTime":"2025-03-21 05:47","pubTimestamp":1742507252,"startTime":"0","endTime":"0","summary":"The Company anticipates that existing cash reserves, and anticipated proceeds from in-the-money warrants, will be sufficient to fund the Company to the third quarter of 2026. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44427292/eupraxia-pharmaceuticals-q4-net-profit-7-5-m-up-from-10-6-m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2521492615","title":"Press Release: Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521492615","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521492615?lang=en_us&edition=fundamental","pubTime":"2025-03-21 05:30","pubTimestamp":1742506200,"startTime":"0","endTime":"0","summary":"VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc.   , a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.\"During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-104GI as a potential treatment for eosinophilic esophagitis, \" said Dr. James Helliwell, Chief Executive Officer of Eupraxia. \"The results from the first six cohorts of the trial show that precise, localized delivery of EP-104GI at higher doses is leading to further improvements in tissue health and symptom reduction outcomes. In addition, during the fourth quarter, we raised C$44.5 million, significantly strengthening our balance sheet and ensuring the Company is we","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","03160","TM","BK4099","BK4555","BK4588","BK4139","BK4604","BK4585"],"gpt_icon":0},{"id":"2517602845","title":"Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602845","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517602845?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:36","pubTimestamp":1741109777,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on March 10 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-virtually-with-craig-hallum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-virtually-with-craig-hallum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2514097775","title":"Eupraxia Pharmaceuticals Shares Rise on Positive Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097775","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514097775?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:30","pubTimestamp":1740493800,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials.Shares traded nearly 6.3% higher in New York at $4.00.The Toronto and New York-listed biotechnology company said that all three patients that were part of the Resolve phase 1b/2a trial evaluating EP-104GI as a treatment reported reduced symptom severity.Eosinophilic esophagitis, or EoE, is a chronic immune system disease where a type of white blood cell, called an eosinophil, builds up in the lining of the esophagus and causes averse reactions to certain foods or allergens.The trial also showed that there was improvement in tissue health among the patients, the largest improvement observed in any of the cohorts to date.Eupraxia said that these effects are comparable to, or better than, what has been demonstrated by currently approved treatments for EoE.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2514385096","title":"Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514385096?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:43","pubTimestamp":1740487431,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. Eupraxia Pharmaceuticals has announced positive results from its RESOLVE Phase 1b/...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-promising-trial-results-for-eosinophilic-esophagitis-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-promising-trial-results-for-eosinophilic-esophagitis-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2514484098","title":"Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514484098","media":"CNW Group","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514484098?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase. Cohort 6 showed the greatest symptom relief scores  of all cohorts to date at 12 weeks. Cohort 6 had the greatest magnitude and percentage change in tissue health scores  of any cohort to date at 12 weeks. Cohort 6 saw the greatest reduction in Peak Eosinophil Count  of any cohort to date. Cohort 5 demonstrated the greatest symptom score reduction  seen to date at 24 weeks, showing continuously improving symptom relief over that time. For tissue health  and PEC there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 showing the greatest response. \"We are highly encouraged by the fact that EP-104GI has demonstrated strong activity despite only being administered to varying portions of the esophagus to this point in the trial. This suggests that maximizing esophageal coverage with EP-104GI could lead to further improvements in histology and symptoms. Based on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eupraxia-pharmaceuticals-announces-positive-data-120000658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EP","BK4213","BK4139","EPRX"],"gpt_icon":0},{"id":"2513720772","title":"Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720772","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513720772?lang=en_us&edition=fundamental","pubTime":"2025-02-22 22:05","pubTimestamp":1740233158,"startTime":"0","endTime":"0","summary":"As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Eupraxia Pharmaceuticals  with a Buy rating and $12 price target Eupraxia is leveraging its DiffuSphere drug delivery technology to develop an extended-release fluticasone propionate corticosteroid injection that has completed a Phase 2b study to treat knee arthritis pain and is in an ongoing Phase 1a/2b study in eosinophilic esophagitis, the analyst tells investors. These programs “illustrate DiffuSphere’s value proposition” by providing efficacy for over six months with a single dose and filling unmet needs in the respective settings, says the firm, which sees “significant upside” around upcoming catalysts this year.Discover the Best Stocks and Maximize Your Portfolio:. See what stocks are receiving strong buy ratings from top-rated analysts.Filter, analyze, and streamline your search for investment opportunities with  TipRanks’ Stock Screener.Eupraxia Pharmaceuticals initiated with a Buy at Craig-Hallum. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/craig-hallum-starts-eupraxia-buy-140558068.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/craig-hallum-starts-eupraxia-buy-140558068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2513426227","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2513426227","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513426227?lang=en_us&edition=fundamental","pubTime":"2025-02-21 20:49","pubTimestamp":1740142183,"startTime":"0","endTime":"0","summary":"Inspirato  shares slumped 54% pre-bell Friday after Thursday's 4.1% increase.TransAct Technologies  shares retreated 30% following a muted session.Eupraxia Pharmaceuticals  shares fell 27%, erasing Thursday's gains.Junee  shares decreased 21% after a 5.1% increase in the previous session.Algoma Steel  shares were down 21%, adding to Thursday's 1% loss.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4170","TACT","JUNE","BK4142","BK4192","EPRX","BK4139","ASTL","ISPO","BK4006"],"gpt_icon":0},{"id":"2512005159","title":"Eupraxia Pharmaceuticals Taps Alex Rothwell as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2512005159","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512005159?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:16","pubTimestamp":1739880960,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals has appointed Alex Rothwell to return as its next chief financial officer, effective immediately.Rothwell brings to the clinical-stage biotechnology company more than 25 years of experience as a business leader and as a senior executive in the Canadian capital markets and investment banking, Eupraxia said Tuesday.He was Eupraxia's CFO from 2018 to 2021.Most recently, Rothwell has been a senior advisor to Fort Capital Partners, a Canadian boutique investment bank.Bruce Cousins, the company's outgoing CFO, is set to retire but will remain as a consultant in the near-term to ensure an orderly transition of responsibilities.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2512156058","title":"Press Release: Eupraxia Pharmaceuticals Announces CFO Succession","url":"https://stock-news.laohu8.com/highlight/detail?id=2512156058","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512156058?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:00","pubTimestamp":1739880000,"startTime":"0","endTime":"0","summary":"-  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role. VICTORIA, BC, Feb. 18, 2025 /CNW/ - Eupraxia Pharmaceuticals Inc.   , a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately.Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.\"I believe that Eupraxia is in an excellent position to create significant value for shareholders, and I'm very focused on helping drive that process. There is significant unrealized - and unrecognized - potential in the assets, and I have confidence that we can deliver on that potential for patients and shareholders,\" said Alex Rothwell, new Chief Financial Officer of Eupraxia. \"EP-104GI h","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4555","BK4585","BK4139","EPRX","03160","TM","BK4588","BK4604"],"gpt_icon":0},{"id":"2484180771","title":"Eupraxia Pharmaceuticals Unveils Promising Drug Delivery Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2484180771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484180771?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:50","pubTimestamp":1732107032,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has revealed promising pharmacokinetic data for its DiffuSpher...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-unveils-promising-drug-delivery-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-unveils-promising-drug-delivery-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2484060192","title":"Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2484060192","media":"CNW Group","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484060192?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:00","pubTimestamp":1732104000,"startTime":"0","endTime":"0","summary":"DiffuSphere is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safety. In clinical trials, a single administration ofDiffuSphere successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagitis or osteoarthritis. DiffuSphere has shown its versatility with various drug classes, supporting the possibility to treat multiple types of pain, infectious diseases, eye diseases and cancers. DiffuSphere, when injected into the esophageal wall , shows a treatment duration exceeding six months from a single injection, with predictable dose control. In Cohort 1 , a steady level of 1.5 pg/ml was maintained for at least six months. In Cohort 5 , 10pg/ml was observed at three months. With this steady, locali","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9YgGICPAvLMgQGyjIASZng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/5d5f1b50e2d7f7cbb1aaa5b66a967dfc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9YgGICPAvLMgQGyjIASZng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/5d5f1b50e2d7f7cbb1aaa5b66a967dfc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eupraxias-diffusphere-technology-demonstrates-targeted-120000820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EPRX","BK4139"],"gpt_icon":1},{"id":"2483861122","title":"Eupraxia Pharmaceuticals Hosts Webinar on Digestive Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2483861122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483861122?lang=en_us&edition=fundamental","pubTime":"2024-11-14 07:02","pubTimestamp":1731538931,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is hosting a webinar on November 15, 2024, focusing on Eosinop...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-hosts-webinar-on-digestive-disorders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-hosts-webinar-on-digestive-disorders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2483866880","title":"Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, \"Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed\", on November 15, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483866880","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483866880?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:00","pubTimestamp":1731535200,"startTime":"0","endTime":"0","summary":"VICTORIA, BC, Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc.   , a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology designed to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, \"Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed\".The event is scheduled to begin at 8:30 am PT / 11:30 am ET on Friday, November 15, 2024.Once registered, participants may begin forwarding their questions for Dr. Helliwell to Tribe Public at research@tribepublic.com, or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mtH5AvrWjAnp94jwLv_ohA--~B/aD00MDA7dz0yOTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9dd3dcd318be0a5ed93ce015dc65cf67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mtH5AvrWjAnp94jwLv_ohA--~B/aD00MDA7dz0yOTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9dd3dcd318be0a5ed93ce015dc65cf67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/eupraxia-pharmaceuticals-ceo-dr-james-220000919.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eupraxia-pharmaceuticals-ceo-dr-james-220000919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EPRX"],"gpt_icon":1},{"id":"2483067417","title":"Eupraxia Pharmaceuticals Reports Promising Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483067417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483067417?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:39","pubTimestamp":1731454793,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial for t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2483062396","title":"Eupraxia reports data from RESOLVE Phase 1b/2a trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2483062396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483062396?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:12","pubTimestamp":1731453139,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-reports-data-from-resolve-phase-1b-2a-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-reports-data-from-resolve-phase-1b-2a-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-20","symbol":"EPRX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2024-08-07","symbol":"EPRX","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2024-05-08","symbol":"EPRX","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2024-04-01","symbol":"EPRX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711944000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1740369600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EPRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EPRX","date":"2025-04-17","current":-4.502059,"percent":0.129167,"low":-5.272862,"twenty":-4.194017,"median":-3.652794,"eighty":-3.261622,"high":-2.905145,"avg":-3.773821,"sd":0.586231,"marketCap":114813917.94},"quantilePoints":[{"date":"2024-04-12","current":-3.449431,"twenty":-3.612259,"median":-3.541416,"eighty":-3.493027,"marketCap":97345692.17},{"date":"2024-04-19","current":-3.387698,"twenty":-3.552309,"median":-3.421661,"eighty":-3.370461,"marketCap":95603540.57},{"date":"2024-04-26","current":-3.593562,"twenty":-3.625516,"median":-3.503926,"eighty":-3.385892,"marketCap":101413189.09},{"date":"2024-05-03","current":-3.426605,"twenty":-3.600947,"median":-3.43788,"eighty":-3.383971,"marketCap":96701521.5},{"date":"2024-05-10","current":-3.385898,"twenty":-3.641329,"median":-3.449431,"eighty":-3.385721,"marketCap":102824445.35},{"date":"2024-05-17","current":-3.411647,"twenty":-3.640071,"median":-3.447632,"eighty":-3.387338,"marketCap":103606411.08},{"date":"2024-05-24","current":-3.304959,"twenty":-3.624933,"median":-3.446108,"eighty":-3.385721,"marketCap":100366460.1},{"date":"2024-05-31","current":-3.270982,"twenty":-3.606012,"median":-3.426605,"eighty":-3.379346,"marketCap":99334650.26},{"date":"2024-06-07","current":-3.128079,"twenty":-3.59449,"median":-3.400672,"eighty":-3.297265,"marketCap":94994862.39},{"date":"2024-06-14","current":-3.11343,"twenty":-3.572704,"median":-3.39476,"eighty":-3.270982,"marketCap":94549996},{"date":"2024-06-21","current":-3.065132,"twenty":-3.533918,"median":-3.390795,"eighty":-3.158235,"marketCap":93083273.6},{"date":"2024-06-28","current":-2.997644,"twenty":-3.518922,"median":-3.386798,"eighty":-3.150268,"marketCap":91033765.58},{"date":"2024-07-05","current":-2.964524,"twenty":-3.496261,"median":-3.38264,"eighty":-3.130777,"marketCap":90027977.81},{"date":"2024-07-12","current":-3.04806,"twenty":-3.473977,"median":-3.37867,"eighty":-3.116162,"marketCap":92564824.23},{"date":"2024-07-15","current":-3.176429,"twenty":-3.468583,"median":-3.358147,"eighty":-3.117527,"marketCap":96463191.25},{"date":"2024-08-02","current":-3.244765,"twenty":-3.46319,"median":-3.337624,"eighty":-3.118893,"marketCap":98538457.15},{"date":"2024-08-09","current":-2.969716,"twenty":-3.451104,"median":-3.295342,"eighty":-3.061718,"marketCap":90185646.42},{"date":"2024-08-16","current":-3.466564,"twenty":-3.451104,"median":-3.304959,"eighty":-3.061718,"marketCap":93592361.75},{"date":"2024-08-23","current":-3.384104,"twenty":-3.470204,"median":-3.33503,"eighty":-3.10203,"marketCap":91366058.16},{"date":"2024-08-30","current":-3.523863,"twenty":-3.501156,"median":-3.37867,"eighty":-3.11285,"marketCap":95139354.42},{"date":"2024-09-06","current":-3.23902,"twenty":-3.491043,"median":-3.37867,"eighty":-3.113358,"marketCap":87448979.97},{"date":"2024-09-13","current":-3.290209,"twenty":-3.473844,"median":-3.339238,"eighty":-3.117527,"marketCap":88831028.95},{"date":"2024-09-20","current":-3.792925,"twenty":-3.501848,"median":-3.346646,"eighty":-3.124951,"marketCap":102403647.17},{"date":"2024-09-27","current":-3.555418,"twenty":-3.530884,"median":-3.380031,"eighty":-3.128079,"marketCap":95991290.18},{"date":"2024-10-04","current":-3.439193,"twenty":-3.513412,"median":-3.384104,"eighty":-3.132127,"marketCap":92853375.28},{"date":"2024-10-11","current":-3.164865,"twenty":-3.50515,"median":-3.380031,"eighty":-3.128079,"marketCap":85446897.71},{"date":"2024-10-18","current":-3.321915,"twenty":-3.50407,"median":-3.37867,"eighty":-3.132127,"marketCap":89687034.19},{"date":"2024-10-25","current":-3.239717,"twenty":-3.501848,"median":-3.343218,"eighty":-3.139567,"marketCap":87467812.52},{"date":"2024-10-31","current":-3.190853,"twenty":-3.494183,"median":-3.336398,"eighty":-3.144156,"marketCap":86148548.98},{"date":"2024-11-08","current":-4.194017,"twenty":-3.516896,"median":-3.345585,"eighty":-3.148333,"marketCap":113232560.89},{"date":"2024-11-15","current":-4.001503,"twenty":-3.578304,"median":-3.378961,"eighty":-3.151996,"marketCap":108034944.63},{"date":"2024-11-22","current":-4.277876,"twenty":-3.617366,"median":-3.380265,"eighty":-3.153485,"marketCap":120724134.84},{"date":"2024-11-29","current":-4.315598,"twenty":-3.637076,"median":-3.385015,"eighty":-3.154757,"marketCap":121788678.49},{"date":"2024-12-06","current":-3.958799,"twenty":-3.666672,"median":-3.386798,"eighty":-3.156853,"marketCap":111719589.87},{"date":"2024-12-13","current":-4.199863,"twenty":-3.701883,"median":-3.394505,"eighty":-3.159839,"marketCap":118522543.03},{"date":"2024-12-20","current":-3.860348,"twenty":-3.791297,"median":-3.399065,"eighty":-3.167178,"marketCap":108941264.94},{"date":"2024-12-27","current":-3.933623,"twenty":-3.884386,"median":-3.403874,"eighty":-3.176429,"marketCap":111009114.19},{"date":"2025-01-03","current":-3.899384,"twenty":-3.911771,"median":-3.415677,"eighty":-3.1789,"marketCap":110042864.17},{"date":"2025-01-10","current":-3.795398,"twenty":-3.902746,"median":-3.425136,"eighty":-3.179766,"marketCap":107108343.23},{"date":"2025-01-17","current":-3.840665,"twenty":-3.890458,"median":-3.439193,"eighty":-3.186485,"marketCap":108385802.51},{"date":"2025-01-24","current":-3.784227,"twenty":-3.907532,"median":-3.443932,"eighty":-3.194003,"marketCap":106793076.99},{"date":"2025-01-31","current":-3.819467,"twenty":-3.904042,"median":-3.448417,"eighty":-3.204251,"marketCap":107787561.51},{"date":"2025-02-07","current":-3.961669,"twenty":-3.907532,"median":-3.455561,"eighty":-3.223118,"marketCap":111800578.77},{"date":"2025-02-14","current":-4.06689,"twenty":-3.933623,"median":-3.464184,"eighty":-3.239003,"marketCap":114769998.94},{"date":"2025-02-21","current":-4.498209,"twenty":-3.941087,"median":-3.477229,"eighty":-3.239159,"marketCap":126942066.57},{"date":"2025-02-28","current":-5.030194,"twenty":-3.968683,"median":-3.503926,"eighty":-3.24072,"marketCap":141954979.49},{"date":"2025-03-07","current":-5.093343,"twenty":-4.02419,"median":-3.515154,"eighty":-3.244739,"marketCap":143737099.57},{"date":"2025-03-14","current":-5.272862,"twenty":-4.052014,"median":-3.550866,"eighty":-3.245793,"marketCap":148803225.9},{"date":"2025-03-21","current":-4.887579,"twenty":-4.122389,"median":-3.594723,"eighty":-3.250028,"marketCap":137930310.39},{"date":"2025-03-28","current":-4.714271,"twenty":-4.153008,"median":-3.612595,"eighty":-3.251401,"marketCap":120225877.54},{"date":"2025-04-04","current":-4.454935,"twenty":-4.170954,"median":-3.623601,"eighty":-3.255676,"marketCap":113612138.22},{"date":"2025-04-11","current":-4.13169,"twenty":-4.173287,"median":-3.640971,"eighty":-3.259344,"marketCap":105368566.21},{"date":"2025-04-17","current":-4.502059,"twenty":-4.194017,"median":-3.652794,"eighty":-3.261622,"marketCap":114813917.94}],"updateTime":1745273692035}}}